Jim Wilson Leaves UPenn Amid Industry Funding Challenges

Jim Wilson, a pioneer in gene therapy, is departing from the University of Pennsylvania due to a significant decrease in industry funding for academic research and various challenges within the gene therapy sector. After years of generating substantial revenue through partnerships, Wilson noted a drastic shift where obtaining funding became increasingly difficult. His departure marks the end of a successful yet turbulent era, characterized by lucrative licensing deals and the establishment of numerous biotech companies. He aims to transition his work into two newly formed companies, reflecting a strategic shift to tackle issues in the worsening funding environment for research.